Hagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, Partow Kebriaei, Elias Jabbour, Michael Rytting, Sergernne York, Farhad Ravandi, Rebecca Garris, Monica Kwari, Stefan Faderl, Jorge Cortes, Richard Champlin and Susan O'Brien Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia Cancer 119
Article first published online: 30 APR 2013 | DOI: 10.1002/cncr.28136
Inotuzumab single-agent therapy is highly active, safe, and convenient in refractory-relapsed acute lymphocytic leukemia. A weekly dose schedule appears to be equally effective and less toxic than a single-dose schedule.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.